--- title: 'Senior Analyst, FP&A at Nurix' canonical: 'https://feeny.ai/job/senior-analyst-fp-a-nurix-brisbane-california-g7qxkkvsfwbf' type: 'job' last_seen: '2026-09-09' --- # Senior Analyst, FP&A at Nurix - **Company:** Nurix - **Location:** Brisbane California, United States - **Posted:** 2026-09-03 - **Last confirmed live:** 2026-09-09 - **Apply:** https://job-boards.greenhouse.io/nurix/jobs/8780786002 ## Job description Senior Analyst, FP&A Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. In this role you will own FP&A and finance business-partner support for Nurix's Research and G&A functions, including budgeting, forecasting, reporting, variance analysis, and accounting close support. It is a high-ownership individual-contributor role for someone who wants to take full responsibility for their areas while partnering closely across the organization. Nurix is a late-stage clinical organization developing targeted protein degradation medicines across a wholly owned and partnered pipeline, so the right candidate is comfortable in a fast-paced, evolving environment and eager to take on new scope as the business grows. Strong attention to detail, cross-functional partnering, problem-solving, and time management are essential. Must be proactive, deadline-oriented, and a self-starter. Essential Duties / Responsibilities - Own the budgeting and forecasting process for Research and G&A in partnership with department and functional leaders - Deliver timely, accurate quarterly reporting and budget-vs-actual analysis for assigned areas with clear variance commentary, and partner with the business monthly to review forecast changes - Manage the quarterly accrual close for Research, working with business partners and external vendors to develop and validate accruals in line with SOX controls and GAAP - Own revenue recognition for Research collaboration agreements (ASC 606), partnering with Accounting - Support the annual financial planning and long-range planning processes - Partner across Finance, Accounting, Research, and G&A functions to support decision-making and ad-hoc analysis - Build and improve financial models and scenario analyses for Research and G&A, including program-level budget and resource-allocation scenarios - Evaluate current processes and systems and drive efficiency improvements, including through automation and AI tooling ## Experience, Knowledge and Skills - 3+ years of experience in an FP&A or Finance function; biotech/pharma a plus - Willingness to learn paired with a genuine appetite to take ownership of their areas - Experience with Planful (or a comparable FP&A planning platform) and NetSuite (or a comparable ERP) a plus - Interest in improving processes through automation/AI a plus - High proficiency in Excel and PowerPoint - Excellent written and verbal communication and presentation skills - Analytical, resilient, and flexible, with a solutions and implementation focus, able to work with minimal supervision in a demanding environment Education - Bachelor's in Finance, Economics, Accounting, or a related field - CPA or MBA a plus Fit with Nurix Culture and Values - Strong team orientation; highly collaborative - Solutions and results-oriented focus - Hands-on approach; resourceful and open to diverse points of view Salary:       $130,000 - $158,900 Location:    Brisbane, CA - Onsite ## About Nurix ## Company Overview - **One-liner**: Nurix Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation medicines to outmatch disease by harnessing the cell’s natural protein disposal system. - **Entity Type**: Public (NASDAQ: NRIX) - **Headquarters**: San Francisco, California, USA - **Founded**: 2009 - **Founders**: Not publicly listed as individual founders; the company was spun out from research at UC Berkeley and UC San Francisco. ## Core Business - **Primary industry**: Biopharmaceuticals / Targeted Protein Degradation - **Target customers**: B2B (pharma partners) and B2C (patients via clinical trials and eventual commercial therapies); enterprise-level partnerships with major pharma. - **Mission or purpose statement**: "Writing medicine’s next chapter using targeted protein degradation as a new script to outmatch disease." [nurixtx.com](https://www.nurixtx.com/) ## Products & Services - **Bexobrutideg (NX-5948)**: A potential best-in-class BTK degrader in Phase 1b/2 clinical trials for relapsed/refractory CLL/SLL and chronic spontaneous urticaria. Co-developed and co-commercialized with Roche under a global collaboration announced June 2026. [nurixtx.com](https://www.nurixtx.com/) - **NX-2127**: A BTK degrader in clinical development for B-cell malignancies. - **CBL-B Inhibitor (NX-1607)**: An E3 ligase inhibitor designed to activate T cells for immuno-oncology, in Phase 1 clinical trials. - **IRAK4 Degrader**: A partnered program with Gilead in Phase 1 for inflammatory diseases. - **STAT6 Degrader**: A partnered program with Sanofi in IND-enabling studies. - **DEL-AI Discovery Engine**: A proprietary, fully AI-integrated platform combining DNA-encoded libraries (DEL), automated chemistry, and machine learning to design and optimize targeted protein degraders and degrader-antibody conjugates (DACs). ## Market Standing - **Valuation/Market Cap**: Not publicly available in the provided search results; as a public company (NRIX), market cap fluctuates daily. Check financial platforms for the latest figure. - **Key Metric**: Annual Revenue (public) — Not publicly available in the provided search results; as a clinical-stage biotech, revenue is typically minimal or pre-revenue. Total funding raised prior to IPO is not detailed in the provided results. - **Notable Investors/Partners**: Roche (global co-development and co-commercialization collaboration for bexobrutideg, announced June 2026), Gilead (partnered IRAK4 degrader program), Sanofi (partnered STAT6 degrader program). - **Growth Signals**: Announced a landmark global collaboration with Roche in June 2026 to co-develop and co-commercialize bexobrutideg across malignant hematology, immunology, and neurology. Presented positive Phase 1a/b data for bexobrutideg in CLL/SLL and chronic spontaneous urticaria in 2026. Multiple partnered and wholly owned pipeline programs advancing through clinical and preclinical stages. ## Competitive Advantages - **Proprietary DEL-AI Discovery Engine**: A fully AI-integrated platform combining DNA-encoded libraries, automated chemistry, and machine learning to design degraders against any protein class, providing a significant speed and innovation advantage. [nurixtx.com](https://www.nurixtx.com/) - **Unparalleled Ligase Expertise**: Deep understanding of E3 ligase biochemistry and biology, a critical and complex component of the protein degradation mechanism, giving them a unique moat. - **Multi-Modal Pipeline**: Developing both small molecule degraders and Degrader-Antibody Conjugates (DACs), expanding the therapeutic reach and creating multiple shots on goal. - **Strong Partnership Network**: Collaborations with top-tier pharma (Roche, Gilead, Sanofi) validate their platform and provide non-dilutive funding and shared risk. ## Strategic Focus - **Clinical Advancement**: Driving lead asset bexobrutideg through pivotal trials in CLL/SLL and expanding into immunology (chronic spontaneous urticaria) and neurology. - **Platform Expansion**: Leveraging the DEL-AI engine to develop Degrader-Antibody Conjugates (DACs) for enhanced cell specificity and safety. - **Pipeline Breadth**: Advancing a multi-modal pipeline across oncology, immunology, and neurology, both wholly owned and through strategic partnerships. - **Partnership Leverage**: Deepening collaborations with Roche, Gilead, and Sanofi to co-develop and co-commercialize programs, reducing risk and accelerating timelines. ## Why Work Here - **Culture**: Mission-focused, values-based, and spirited culture emphasizing "breakthrough innovation," "leadership," "accountability," and "zealousness." Employees are encouraged to "think big and act bold." [nurixtx.com](https://www.nurixtx.com/work-at-nurix/) - **Work with Industry Leaders**: The team includes scientific innovators who built the protein degradation field, seasoned executives with biotech scaling expertise, and leading clinicians. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/) - **Growth & Impact**: Employees can "wear many hats" and gain broad exposure in a lean, virtual drug developer environment. The company emphasizes career growth and opportunity-rich experiences. - **Work Policy**: Onsite in Brisbane, CA (San Francisco Bay Area) for most roles, as indicated by job postings. [nurixtx.com](https://www.nurixtx.com/explore-jobs/) - **Benefits**: Comprehensive health and welfare plans, enhanced parental leave, wellness reimbursement, 401(k) employer match, and a highly collaborative culture. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/) - **Engineering/Science Culture**: Described as "mission-focused, values-based, and spirited," with a focus on "intellectual and technical ingenuity" and "intelligent risk-taking." The company is a "virtual drug developer" with a lean internal infrastructure, relying on SaaS and cloud platforms. [nurixtx.com](https://www.nurixtx.com/explore-jobs/) ## Sources 1. [nurixtx.com](https://www.nurixtx.com/) 2. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/) 3. [nurixtx.com](https://www.nurixtx.com/explore-jobs/) 4. [nurixtx.com](https://www.nurixtx.com/our-story/) ## Other roles at Nurix - [Associate Director, electronic Quality Management System (eQMS)](https://feeny.ai/job/associate-director-electronic-quality-management-system-eqms-nurix-brisbane-k35rdgj6th4k) — Brisbane, CA - [Director, Nonclinical Toxicology Operations](https://feeny.ai/job/director-nonclinical-toxicology-operations-nurix-brisbane-california-a7ynjr847xvh) — Brisbane California, United States - [Director, Medical Affairs - Immunology](https://feeny.ai/job/director-medical-affairs-immunology-nurix-brisbane-california-8q3w67dea5xq) — Brisbane California, United States - [Senior Manager/Associate Director, Regulatory Affairs (Strategy, Hematology Oncology)](https://feeny.ai/job/senior-manager-associate-director-regulatory-affairs-strategy-hematology-zsgdf1qycbew) — Brisbane California, United States - [Senior Administrative Assistant, R&ED](https://feeny.ai/job/senior-administrative-assistant-r-ed-nurix-brisbane-california-9k9rhmyvd955) — Brisbane California, United States - [Senior Director, Quality Control](https://feeny.ai/job/senior-director-quality-control-nurix-brisbane-california-d4hqe06vb3t7) — Brisbane California, United States - [Associate Director, Chemical Engineering](https://feeny.ai/job/associate-director-chemical-engineering-nurix-brisbane-california-6gbpc8ben8eh) — Brisbane California, United States - [Medical Director / Senior Medical Director](https://feeny.ai/job/medical-director-senior-medical-director-nurix-brisbane-california-wkgs5dx1e7eq) — Brisbane California, United States - [Medical Director / Senior Medical Director](https://feeny.ai/job/medical-director-senior-medical-director-nurix-brisbane-california-57ydhjmqgfm6) — Brisbane California, United States - [Medical Director / Senior Medical Director 5948-306](https://feeny.ai/job/medical-director-senior-medical-director-5948-306-nurix-brisbane-california-4130rhzkqwev) — Brisbane California, United States